Kirsten Minden1, Gerd Horneff2, Martina Niewerth3, Eva Seipelt4, Martin Aringer5, Peer Aries6, Ivan Foeldvari7, Johannes-Peter Haas8, Ariane Klein9, Stefanie Tatsis10, Klaus Tenbrock11, Angela Zink1, Jens Klotsche1. 1. German Rheumatism Research Center and Charité-University Medicine Berlin, Berlin, Germany. 2. Asklepios Clinic Sankt Augustin GmbH, Sankt Augustin, and University Hospital of Cologne, Cologne, Germany. 3. German Rheumatism Research Center, Berlin, Germany. 4. Immanuel Krankenhaus, Berlin, Germany. 5. University Medical Center Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany. 6. Rheumatologie im Struensee-Haus, Hamburg, Germany. 7. Centre for Pediatric and Adolescent Rheumatology, Hamburg, Germany. 8. German Centre for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany. 9. Asklepios Clinic Sankt Augustin GmbH, Sankt Augustin, Germany. 10. Kath. Marienkrankenhaus, Hamburg, Germany. 11. Rheinisch-Westfälische Technische Hochschule Aachen University, Aachen, Germany.
Abstract
OBJECTIVE: To study juvenile idiopathic arthritis (JIA) long-term outcomes in relation to the time of initiation of biologic disease-modifying antirheumatic drug (bDMARD). METHODS: Outcomes of JIA patients prospectively followed by the Biologika in der Kinderrheumatologie (BiKeR) and Juvenile Arthritis Methotrexate/Biologics Long-Term Observation (JuMBO) registers were analyzed with regard to drug-free remission and inactive disease, functional status and quality of life, and surgery. To analyze the influence of early bDMARD therapy on outcomes, patients were assigned to 3 groups based on the time from symptom onset to bDMARD start (G1: ≤2 years, G2: >2 to ≤5 years, and G3: >5 years). Propensity score-adjusted outcome differences were analyzed by multinomial logistic regression analyses among the groups. RESULTS: A total of 701 JIA patients were observed for mean ± SD 9.1 ± 3.7 years. At the last follow-up (disease duration mean ± SD 14.3 ± 6.1 years), 11.7% of patients were in drug-free remission, and 40.0% had inactive disease. More than half of the patients reported no functional limitation, while 5% had undergone arthroplasty, and 3% had eye surgery. At the 10-year time point, patients in G1 (n = 108) were significantly more likely to be in drug-free remission than those patients who began treatment later (G2, n = 199; G3, n = 259), with 18.5%, 10.1%, and 4.9%, respectively. Patients in G1 had significantly lower disease activity (clinical Juvenile Arthritis Disease Activity Score in 10 joints = 4.9), a better overall well-being (18.2% patient global assessment score = 0), and higher functional status (59.2% Health Assessment Questionnaire score = 0), compared to patients in G3 (7.1, 8.4%, and 43.7%, respectively). G1 patients required arthroplasty significantly less frequently than G3 patients and had significantly lower disease activity over time than patients in both G2 and G3. CONCLUSION: Early DMARD treatment is associated with better disease control and outcomes, which supports the concept of a "window of opportunity" for JIA.
OBJECTIVE: To study juvenile idiopathic arthritis (JIA) long-term outcomes in relation to the time of initiation of biologic disease-modifying antirheumatic drug (bDMARD). METHODS: Outcomes of JIA patients prospectively followed by the Biologika in der Kinderrheumatologie (BiKeR) and Juvenile ArthritisMethotrexate/Biologics Long-Term Observation (JuMBO) registers were analyzed with regard to drug-free remission and inactive disease, functional status and quality of life, and surgery. To analyze the influence of early bDMARD therapy on outcomes, patients were assigned to 3 groups based on the time from symptom onset to bDMARD start (G1: ≤2 years, G2: >2 to ≤5 years, and G3: >5 years). Propensity score-adjusted outcome differences were analyzed by multinomial logistic regression analyses among the groups. RESULTS: A total of 701 JIA patients were observed for mean ± SD 9.1 ± 3.7 years. At the last follow-up (disease duration mean ± SD 14.3 ± 6.1 years), 11.7% of patients were in drug-free remission, and 40.0% had inactive disease. More than half of the patients reported no functional limitation, while 5% had undergone arthroplasty, and 3% had eye surgery. At the 10-year time point, patients in G1 (n = 108) were significantly more likely to be in drug-free remission than those patients who began treatment later (G2, n = 199; G3, n = 259), with 18.5%, 10.1%, and 4.9%, respectively. Patients in G1 had significantly lower disease activity (clinical Juvenile Arthritis Disease Activity Score in 10 joints = 4.9), a better overall well-being (18.2% patient global assessment score = 0), and higher functional status (59.2% Health Assessment Questionnaire score = 0), compared to patients in G3 (7.1, 8.4%, and 43.7%, respectively). G1 patients required arthroplasty significantly less frequently than G3 patients and had significantly lower disease activity over time than patients in both G2 and G3. CONCLUSION: Early DMARD treatment is associated with better disease control and outcomes, which supports the concept of a "window of opportunity" for JIA.
Authors: Daniel J Lovell; Hermine I Brunner; Andreas O Reiff; Lawrence Jung; Katerina Jarosova; Dana Němcová; Richard Mouy; Christy Sandborg; John F Bohnsack; Dirk Elewaut; Christos Gabriel; Gloria Higgins; Isabelle Kone-Paut; Olcay Y Jones; Veronika Vargová; Elizabeth Chalom; Carine Wouters; Ivan Lagunes; Yanna Song; Alberto Martini; Nicolino Ruperto Journal: RMD Open Date: 2020-07
Authors: Varvara Choida; Margaret Hall-Craggs; Bethany R Jebson; Corinne Fisher; Maria Leandro; Lucy R Wedderburn; Coziana Ciurtin Journal: Front Pharmacol Date: 2021-02-02 Impact factor: 5.810
Authors: Fernando García-Rodríguez; Augusto Gamboa-Alonso; Sol Jiménez-Hernández; Lucero Ochoa-Alderete; Valeria Alejandra Barrientos-Martínez; Neri Alejandro Alvarez-Villalobos; Gabriela Andrea Luna-Ruíz; Ingris Peláez-Ballestas; Ana Victoria Villarreal-Treviño; Manuel Enrique de la O-Cavazos; Nadina Rubio-Pérez Journal: Pediatr Rheumatol Online J Date: 2021-10-09 Impact factor: 3.054
Authors: Annie Yarwood; Stephanie Shoop-Worrall; Elena López-Isac; Samantha Louise Smith; Andrew P Morris; John David Bowes; Melissa Tordoff; Kimme L Hyrich; Wendy Thomson; Stephen Eyre Journal: Rheumatology (Oxford) Date: 2022-10-06 Impact factor: 7.046